Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan I Silverberg

Showing results (381-390 of 670) with videos related to

Pageof 67
Sort By:
Dermatology and Therapy|October 23, 2018
Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their FamiliesEric L Simpson, Amy S Paller, Mark Boguniewicz, et al.
Dermatology and Therapy|November 30, 2021
Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16Jonathan I Silverberg, Mark Boguniewicz, Jill Waibel, et al.
Dermatology and Therapy|August 6, 2022
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b TrialMelinda J Gooderham, Giampiero Girolomoni, Julian O Moore, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 31, 2024
Drug survival of alitretinoin treatment for chronic hand eczema: A Danish nationwide cohort studyAmalie Thorsti Møller Rønnstad, Mia-Louise Nielsen, Christoph Schlapbach, et al.
Journal of Drugs in Dermatology : JDD|February 2, 2024
Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic DermatitisLawrence F Eichenfield, Jonathan I Silverberg, Adelaide A Hebert, et al.
Journal of Drugs in Dermatology : JDD|January 28, 2020
Topical Agents for the Treatment of Atopic DermatitisLawrence F. Eichenfield, Thomas Luger, Kim Papp, et al.
Journal of the American Academy of Dermatology|July 18, 2018
Response to "Comment on: 'When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council'"Eric L Simpson, Nick J Reynolds, Carsten Flohr, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|March 14, 2023
Burden of Disease and Unmet Needs in Atopic Dermatitis: Results From a Patient SurveyJonathan I Silverberg, Jennifer A Mohawk, Joshua Cirulli, et al.
JAAD International|January 5, 2026
Utilization and predictors of use of immunomodulators for atopic dermatitis: A cohort studyPriyanka Anand, Arash Mostaghimi, Robert Glynn, et al.
Dermatologic Therapy|October 21, 2022
Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long-term efficacy and patient-reported outcomesEric Simpson, April Armstrong, Mark Boguniewicz, et al.
Pageof 67

Showing results (381-390 of 670) with videos related to

Sort By:
Pageof 67
Dermatology and Therapy|October 23, 2018
Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their FamiliesEric L Simpson, Amy S Paller, Mark Boguniewicz, et al.
Dermatology and Therapy|November 30, 2021
Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16Jonathan I Silverberg, Mark Boguniewicz, Jill Waibel, et al.
Dermatology and Therapy|August 6, 2022
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b TrialMelinda J Gooderham, Giampiero Girolomoni, Julian O Moore, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 31, 2024
Drug survival of alitretinoin treatment for chronic hand eczema: A Danish nationwide cohort studyAmalie Thorsti Møller Rønnstad, Mia-Louise Nielsen, Christoph Schlapbach, et al.
Journal of Drugs in Dermatology : JDD|February 2, 2024
Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic DermatitisLawrence F Eichenfield, Jonathan I Silverberg, Adelaide A Hebert, et al.
Journal of Drugs in Dermatology : JDD|January 28, 2020
Topical Agents for the Treatment of Atopic DermatitisLawrence F. Eichenfield, Thomas Luger, Kim Papp, et al.
Journal of the American Academy of Dermatology|July 18, 2018
Response to "Comment on: 'When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council'"Eric L Simpson, Nick J Reynolds, Carsten Flohr, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|March 14, 2023
Burden of Disease and Unmet Needs in Atopic Dermatitis: Results From a Patient SurveyJonathan I Silverberg, Jennifer A Mohawk, Joshua Cirulli, et al.
JAAD International|January 5, 2026
Utilization and predictors of use of immunomodulators for atopic dermatitis: A cohort studyPriyanka Anand, Arash Mostaghimi, Robert Glynn, et al.
Dermatologic Therapy|October 21, 2022
Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long-term efficacy and patient-reported outcomesEric Simpson, April Armstrong, Mark Boguniewicz, et al.
Pageof 67